AU6903800A - Novel protein phosphatases and diagnosis and treatment of phosphatase-related disorders - Google Patents

Novel protein phosphatases and diagnosis and treatment of phosphatase-related disorders

Info

Publication number
AU6903800A
AU6903800A AU69038/00A AU6903800A AU6903800A AU 6903800 A AU6903800 A AU 6903800A AU 69038/00 A AU69038/00 A AU 69038/00A AU 6903800 A AU6903800 A AU 6903800A AU 6903800 A AU6903800 A AU 6903800A
Authority
AU
Australia
Prior art keywords
phosphatase
diagnosis
treatment
related disorders
novel protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU69038/00A
Inventor
Peter Flanagan
Ron Hill
Mario Lioubin
Ricardo Martinez
Gregory D. Plowman
David Whyte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of AU6903800A publication Critical patent/AU6903800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048Protein-tyrosine-phosphatase (3.1.3.48)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
AU69038/00A 1999-08-13 2000-08-11 Novel protein phosphatases and diagnosis and treatment of phosphatase-related disorders Abandoned AU6903800A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14900599P 1999-08-13 1999-08-13
US60149005 1999-08-13
PCT/US2000/022158 WO2001012819A2 (en) 1999-08-13 2000-08-11 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders

Publications (1)

Publication Number Publication Date
AU6903800A true AU6903800A (en) 2001-03-13

Family

ID=22528389

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69038/00A Abandoned AU6903800A (en) 1999-08-13 2000-08-11 Novel protein phosphatases and diagnosis and treatment of phosphatase-related disorders

Country Status (5)

Country Link
EP (1) EP1212433A2 (en)
JP (1) JP2003507016A (en)
AU (1) AU6903800A (en)
CA (1) CA2377662A1 (en)
WO (1) WO2001012819A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4367600A (en) * 1999-07-02 2001-01-22 Ceptyr, Inc. Dsp-3 dual-specificity phosphatase
US7504223B2 (en) * 1999-08-05 2009-03-17 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Knockout mouse for the tumor suppressor gene ANX7
US6420153B1 (en) 2000-02-29 2002-07-16 Millennium Pharmaceuticals, Inc. 18232, a novel dual specificity phosphatase and uses therefor
EP1268818A2 (en) * 2000-03-24 2003-01-02 Millennium Pharmaceuticals, Inc. 18221, dual specificity phosphatase and uses thereof
WO2002010363A2 (en) * 2000-07-28 2002-02-07 Incyte Genomics, Inc. Protein phosphatases
AU2002212164A1 (en) * 2000-09-07 2002-03-22 Bayer Aktiengesellschaft Regulation of human map kinase phosphatase-like enzyme
AU2001291824A1 (en) * 2000-09-11 2002-03-22 Bayer Aktiengesellschaft Regulation of human tyrosine phosphatase-like enzyme
US6825021B2 (en) * 2000-09-19 2004-11-30 Ceptyr, Inc. DSP-15 dual-specificity phosphatase
JP2004514434A (en) * 2000-11-20 2004-05-20 ピーイー コーポレーション (エヌワイ) Isolated human phosphatase protein, nucleic acid molecule encoding human phosphatase protein and uses thereof
MXPA03005436A (en) 2000-12-20 2004-05-05 Bristol Myers Squibb Co Polynucleotides encoding novel human phosphatases.
WO2002090530A2 (en) * 2001-01-18 2002-11-14 Incyte Genomics, Inc. Kinases and phosphatases
JPWO2003038118A1 (en) * 2001-10-31 2005-02-24 藤沢薬品工業株式会社 Method for evaluating phosphatase inhibitor
WO2003044161A2 (en) * 2001-11-15 2003-05-30 Tularik Inc. Gene amplification and overexpression in cancer
AU2003212162A1 (en) * 2002-03-28 2003-10-13 Qlt Inc. Cancer associated protein phosphatases and their uses
WO2004028554A2 (en) * 2002-09-27 2004-04-08 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Skrp, astray, string, vacm associated with metabolic control
GB2465907B (en) 2007-08-10 2013-07-10 Agency Science Tech & Res VHZ for diagnosis and treatment of cancer
US9580513B2 (en) 2008-08-08 2017-02-28 Agency For Science, Technology And Research (A*Star) VHZ for diagnosis and treatment of cancers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8479498A (en) * 1997-07-08 1999-02-08 Cold Spring Harbor Laboratory Dual specificity phosphatase and methods of use
WO2000006728A2 (en) * 1998-07-28 2000-02-10 Incyte Pharmaceuticals, Inc. Phosphorylation effectors
AU6410599A (en) * 1998-09-30 2000-04-17 Millennium Pharmaceuticals, Inc. Novel protein phosphatase molecules and uses therefor
EP1192257A2 (en) * 1999-03-18 2002-04-03 Incyte Pharmaceuticals, Inc. Human regulators of intracellular phosphorylation
US6852520B1 (en) * 1999-03-24 2005-02-08 Ceptyr, Inc. DSP-2 dual-specificity phosphatase
CA2367104A1 (en) * 1999-04-07 2000-10-12 Ceptyr, Inc. Dsp-7 dual-specificity map kinase phosphatase
AU4213100A (en) * 1999-04-07 2000-10-23 Ceptyr, Inc. Dsp-4 dual-specificity map kinase phosphatase
AU4470200A (en) * 1999-04-20 2000-11-02 Ceptyr, Inc. Dsp-8 dual-specificity map kinase phosphatase
EP1173587A1 (en) * 1999-04-23 2002-01-23 Ceptyr, Inc. Dsp-10 dual-specificity map kinase phosphatase
US6645753B1 (en) * 1999-04-27 2003-11-11 Ceptyr, Inc. DSP-5 dual-specificity phosphatase
AU4367600A (en) * 1999-07-02 2001-01-22 Ceptyr, Inc. Dsp-3 dual-specificity phosphatase
US6649391B1 (en) * 1999-07-20 2003-11-18 Ceptyr, Inc. DSP-11 dual-specificity phosphatase
CA2383927A1 (en) * 1999-09-15 2001-03-22 Incyte Genomics, Inc. Protein phosphatase and kinase proteins

Also Published As

Publication number Publication date
WO2001012819A3 (en) 2002-01-24
EP1212433A2 (en) 2002-06-12
CA2377662A1 (en) 2001-02-22
WO2001012819A2 (en) 2001-02-22
JP2003507016A (en) 2003-02-25

Similar Documents

Publication Publication Date Title
AU7722600A (en) Compositions and methods for the diagnosis and treatment of immune disorders
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
AU6903800A (en) Novel protein phosphatases and diagnosis and treatment of phosphatase-related disorders
AUPQ415899A0 (en) Compositions for and methods of treatment of allergic diseases
AU5840200A (en) Treatment of diabetes and related pathologies
AU6205700A (en) Azo amino acid derivatives for the treatment of neurological diseases
AU5309600A (en) Compositions and methods for the treatment and diagnosis of immune disorders
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU9551298A (en) Use of coumarin derivatives for the treatment of digestive tract disorders
AU1356201A (en) Treatment of hyperproliferative disorders
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
AU5908300A (en) Prevention and treatment of amyloid-associated disorders
AU3896900A (en) Treatment of pain
AUPQ201499A0 (en) Treatment of inflammatory and malignant diseases
GB2361872B (en) Diagnosis of medical disorders
AU7106300A (en) Treatment of skin disorders
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU4215499A (en) Treatment of neurodegenerative diseases
AU2432001A (en) Treatment of mental conditions including depression
AU7260098A (en) Diagnosis and treatment of phosphatase 0r kinase-related disorders
AU3899100A (en) Treatment of hyperactivity disorders
AU1405001A (en) Treatment of diseases
AU2001258575A1 (en) Treatment of cancer and neurological diseases
GB9908059D0 (en) Diagnosis and treatment of diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase